The Half-Year Exam of the 'World's First AI Drug Delivery Stock': 134-Fold Revenue, What's the Real Story?

Summary

This company, dubbed the 'world's first AI drug delivery stock,' released its half-year report showing revenue up 134-fold year-over-year, but the US market contributed 137.9 million yuan, accounting for 89.35% of total revenue, with the single largest customer also representing 89.35%, indicating extreme customer concentration risk.